Hvis samtidig administration af ketoconazol, eller andre potente CYP3A4 - hæmmere, og ABILIFY overvejes, bør eventuelle fordele opveje potentielle risici for patienten.
When considering concomitant administration of ketoconazole or other potent CYP3A4 inhibitors with ABILIFY, potential benefits should outweigh the potential risks to the patient.